11/06/2018

Tagrisso® (Osimertinib) NCCN Status Update

Tagrisso® (Osimertinib) is now the only preferred first-line EGFR TKI in the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines^®).

I am excited to share with you that first-line Tagrisso® (Osimertinib) has been elevated to preferred status in the NCCN Guidelines^®, for sensitizing EGFR mutation-positive metastatic NSCLC. 

Tagrisso® (Osimertinib) preferred status among all Category 1 recommended EGFR TKI options, is the first time the National Comprehensive Cancer Network^® (NCCN^®) has given this status in the EGFR TKI

Tagrisso® (Osimertinib) is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Please see the complete Prescribing Information including Patient information.